CYP19A1 and breast cancer: In addition to Tamoxifen and Aromatase Inhibitors, a broader spectrum of hormonal therapies, including Nitriles, Triazoles, and other estrogen antagonists, has emerged as a promising avenue in breast cancer treatment (51, 52).